The global biopharmaceutical leader Novo Nordisk has successfully completed the pilot run of its modern warehousing center in the Pudong Airport Comprehensive Bonded Zone.
The first batch of diabetes treatment drugs imported from Denmark cleared customs smoothly through frontline declaration, setting a new benchmark for multinational pharmaceutical companies to establish modern supply chains in China.
Founded in 1923 and headquartered in Copenhagen, Denmark, Novo Nordisk achieved 18 percent global sales growth in the first quarter of 2025.
During the pilot phase, the project focused on validating core processes including customs clearance efficiency, cold chain management, and digital system integration. Through this facility, Novo Nordisk will further solidify Pudong's role as a critical node in its global supply chain while strengthening Shanghai's position as the commercial and innovation hub for its China operations.
Notably, China's diabetic population exceeded 148 million in 2024, with an increasingly younger demographic trend. When fully operational, the warehouse will distribute medications and devices for diabetes, obesity, and other therapeutic areas.
Seizing opportunities from strategic emerging industry transformations and global corporate realignments, the Pudong Airport Comprehensive Bonded Zone has established a "triple-engine" service system through institutional innovation, policy empowerment, and technological support. This system delivers efficient and transparent supply chain solutions for multinational pharma companies, enhances coordination between local production and import trade, and improves cross-border supply chain resilience.
The zone has now developed four core industrial clusters specializing in integrated circuits, healthcare, premium consumer goods, and aviation support services.
